Jaguar Health (NASDAQ:JAGX) Stock Price Crosses Below 50-Day Moving Average of $2.33

Jaguar Health, Inc. (NASDAQ:JAGX – Get Rating)’s share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.33 and traded as low as $1.04. Jaguar Health shares last traded at $1.05, with a volume of 7,129,006 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Jaguar Health from a “sell” rating to a “hold” rating in a research report on Wednesday, February 8th.

Jaguar Health Price Performance

The company has a debt-to-equity ratio of 5.56, a quick ratio of 0.69 and a current ratio of 0.94. The company has a market cap of $2.03 million, a P/E ratio of -0.01 and a beta of 1.83. The firm has a 50 day moving average price of $2.33 and a two-hundred day moving average price of $0.92.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in JAGX. Citigroup Inc. bought a new position in Jaguar Health in the 1st quarter worth about $34,000. Goldman Sachs Group Inc. boosted its stake in Jaguar Health by 153.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 33,148 shares during the period. Bank of New York Mellon Corp boosted its stake in Jaguar Health by 507.3% in the 1st quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 141,796 shares during the period. Virtu Financial LLC boosted its stake in Jaguar Health by 76.1% in the 1st quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 99,073 shares during the period. Finally, Millennium Management LLC boosted its stake in Jaguar Health by 152.3% in the 2nd quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 321,795 shares during the period. Institutional investors own 11.77% of the company’s stock.

Jaguar Health Company Profile

(Get Rating)

Jaguar Health, Inc is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.